Nyrada, Inc. · ASX:NYR
Nyrada — Investor Presentation (October 2024)
20 slides from Nyrada's investor presentation, Oct 28, 2024
Slide 1: Investor Presentation October 2024
For personal use only Investor Presentation October 2024 Improving Lives, Offering Hope Authorised by Mr. John Moore, Non-Executive Chair, on behalf of the Board. ASX:NYR
Slide 2: Important Notice and Disclaimer
Important Notice and Disclaimer This presentation has been prepared by Nyrada Inc (“NYR” or “Company”). It should not be Such forward-looking statements do not guarantee of future performance and involve known considered as an offer or invitation to subscribe for, or purchase any securities in NYR,
Slide 3: About Nyrada
About Nyrada › Drug discovery and development company specialising in rational design of novel small molecule therapeutics. For personal use only › Nyrada’s lead drug candidate NYR-BI03: › demonstrated strong preclinical efficacy protecting the brain from secondary injury following stroke. › demonst
Slide 4: Company Snapshot
Company Snapshot Company Structure Leadership For personal use only * Includes options approved but not issued and options to be considered at 12 Nov. 2024 Annual General Meeting Share Register – 24 October 2024 Price Chart 4
Slide 5: Nyrada Offer (1)
Nyrada Offer (1) › Nyrada Inc. (ASX:NYR) proposes to raise up to AU$4.36 million (before costs) in new equity capital to fund new and For personal use only existing growth opportunities. › Details of Placement: › 28,000,000 CDIs through placement to sophisticated and institutional investors › Placem
Slide 6: Nyrada Offer (2)
Nyrada Offer (2) › Use of Funds › Completion of Phase Ia clinical trial for NYR-BI03 For personal use only › Preparation and submission of Investigational New Drug (IND) applications with the US Food and Drug Administration (FDA) › Further research and development of NYR-BI03 in cardiac heart diseas
Slide 7: Investment Proposition
Investment Proposition › Pioneering transient receptor potential canonical (TRPC) For personal use only channel blocking therapies. › Commencing first-in-human Phase Ia clinical trial in late 2024. › First-in-class neuroprotection and cardioprotection therapy with novel mode of action. › One drug as
Slide 8: Nyrada's Lead Drug Candidate NYR-BI03
Nyrada’s Lead Drug Candidate NYR-BI03 For personal use only First-in-Class with Novel Significant Unmet Clinical Need Mechanism of Action and Market Opportunity › NYR-BI03 is a first-in-class therapy. › Targeting multiple indications. › Novel mechanism of action. › Stroke, TBI and ischemia- Reperfus
Slide 9: One Drug, Two Applications, Three Markets
One Two Three Drug Applications Markets For personal use only STROKE NYR-BI03 Neuroprotection Commencing ~US$52.2 billion by 20322 Phase Ia clinical trial in late CY2024 TRAUMATIC BRAIN INJURY ~US$5.5 billion by 20344 Cardioprotection MYOCARDIAL INFARCTION ~US$3.7 billion by 20325 9
Slide 10: Neuroprotection – Stroke and TBI
Neuroprotection – Stroke and TBI Serial reconstruction from MRI For personal use only Secondary Disability Primary Injury Injury Level 30 mins BECAME STAYED THE DIED WORSE SAME IMPROVED 72 hours Hours Days Weeks Months Reduce secondary injury resulting from stroke or TBI Nyrada drug NYR-BI03 • Impro
Slide 11: Cardioprotection
Cardioprotection Key Preclinical Results: NYR-BI03 showed strong For personal use only efficacy limiting cardiovascular damage resulting from myocardial ischemia-reperfusion (IR) injury • 86% Cardioprotection • 43% increase in left ventricular ejection fraction • 50% increase in fractional shortenin
Slide 12: Indicative Phase I Study Design
Indicative Phase I Study Design For personal use only OBJECTIVES To assess the safety, tolerability, and pharmacokinetics of NYR-BI03 DESIGN • Randomised, double-blind PARTICIPANTS placebo –controlled, dose escalation design • Male and female healthy volunteers • 5 cohorts; 8 participants each • 18
Slide 13: Near Term Catalysts
Near Term Catalysts Catalysts For personal use only › 2HCY2024 – NYR-BI03 GLP study updates Late CY2024 NYR-BI03 Clinical Trial Commencement › 3QCY2024 – WRAIR TBI study update Early CY2025 WRAIR TBI study readout › 4QCY2024 – NYR-BI03 Human Research Ethics application submission 1HCY2025 Progressiv
Slide 14: High Calibre Board with international experience
High Calibre Board with international experience For personal use only › Nyrada operates under the direction of a governing board of international calibre John Moore Dr Ian Dixon Dr Gisela Mautner › Strong track record in realising the Non-Executive Chair Non-Executive Director Non-Executive Directo
Slide 15: Management Team with Proven Industry Experience
Management Team with Proven Industry Experience For personal use only James Bonnar - CEO Cameron Jones - CFO Dr Benny Evison - CSO Supported by specialist advisers: › Business executive with 25 years › Finance executive with experience as › More than 20 years of experience of experience in healthcar
Slide 16: Large Market Opportunity – Stroke
Large Market Opportunity – Stroke For personal use only Globally: ~15 million ~5 million people suffer left permanently strokes annually1 disabled1 One approved drug class for stroke suitable for <15% of patients (tPA - tissue plasminogen activator). Effective treatment will improve patient outcomes
Slide 17: Large Market Opportunity – Traumatic Brain Injury (TBI)
Large Market Opportunity – Traumatic Brain Injury (TBI) For personal use only Globally: ~5.5 million ~55 million people suffer severe living with effects of TBA annually3 medically treated TBI3 No current FDA approved treatments Effective treatment will improve patient outcomes and reduce high costs
Slide 18: Large Market Opportunity – Myocardial Infarction
Large Market Opportunity – Myocardial Infarction For personal use only Globally: ~15-20 million ~15% people suffer heart mortality within 30 attack annually days No current FDA approved treatments targeting myocardial infarction-reperfusion injury Effective treatment will improve patient outcomes an
Slide 19: References
References 1 – World Health Organization - https://www.emro.who.int/health-topics/stroke-cerebrovascular- For personal use only accident/index.html#:~:text=Annually%2C%2015%20million%20people%20worldwide,cause%20i s%20high%20blood%20pressure 2 – Databridge Market Research - https://www.databridgemar
Slide 20: For personal use only
For personal use only @nyrada_inc @nyrada_inc info@nyrada.com www.nyrada.com 20